<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802605</url>
  </required_header>
  <id_info>
    <org_study_id>BEMI-2015</org_study_id>
    <nct_id>NCT02802605</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients</brief_title>
  <acronym>BEMI-2015</acronym>
  <official_title>Randomized and Controlled Trial on the Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Marqués de Valdecilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospectively evaluation of the incidence of thromboembolic events in hospitalized cirrhotic&#xD;
      patients. 2. Efficacy and safety of use of bemiparin in preventing peripheral and portal&#xD;
      thrombosis. 3. Monitoring antiXa levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE: To evaluate the safety of prophylactic anticoagulation Bemiparina (HIBOR®)&#xD;
      for the prevention of peripheral and portal vein thrombosis in cirrhotic patients with&#xD;
      prolonged hospitalization.&#xD;
&#xD;
      Secondary objectives are the following:&#xD;
&#xD;
        1. To evaluate the incidence of thrombotic events in hospitalized cirrhotic patients.&#xD;
&#xD;
        2. To evaluate the efficacy of low molecular weight heparin (HIBOR 3.500UI) in preventing&#xD;
           thrombotic events in hospitalized cirrhotic patients.&#xD;
&#xD;
        3. To identify risk factors for development of portal vein thrombosis and deep vein&#xD;
           thrombosis in hospitalized patients.&#xD;
&#xD;
        4. Evaluate the morbidity and mortality associated with thromboembolic events.&#xD;
&#xD;
        5. Evaluate prophylactic anticoagulation levels by determining antiXa and antithrombin III.&#xD;
&#xD;
        6. To study the expression profile and functionality of Toll-like receptors as factors&#xD;
           intimately involved in the inflammatory response, as well as the variability of&#xD;
           different serum markers associated with proinflammatory state: I-FABP / IL6-IL8 / NO,&#xD;
           endothelin and LPS-binding protein.&#xD;
&#xD;
        7. Evaluate the effect on liver fibrosis (by Fibroscan®) and serum TGF&#xD;
&#xD;
        8. Evolution of hepatocellular function estimated by the scores of Child-Pugh and MELD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with bleeding and liver toxicity under Bemiparin treatment (HIBOR®) for the prevention of DVT / portal vein thrombosis.</measure>
    <time_frame>90 days</time_frame>
    <description>The bleeding will be classificated in two grades ( mild/ severe) and hepatoxicty were asses according to NCI CTCAE Version 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of thrombotic events in cirrhotic hospitalized patients</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Cirrhosis and Coagulation</condition>
  <arm_group>
    <arm_group_label>Bemiparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bemiparin 3.500 U, once a day during hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No drug</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Clinical practice as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemiparin</intervention_name>
    <description>Bemiparin subcutaneus administration</description>
    <arm_group_label>Bemiparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Liver cirrhosis of any etiology diagnosed by previous biopsy or clinical, laboratory&#xD;
             and sonographic criteria&#xD;
&#xD;
          2. Hospital admission at least 3 days, because of decompensated liver disease (ascites,&#xD;
             encephalopathy, controlled gastrointestinal bleeding, spontaneous bacterial&#xD;
             peritonitis)&#xD;
&#xD;
          3. signed written consent&#xD;
&#xD;
          4. Women of child-bearing age use effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 and &gt;80 years&#xD;
&#xD;
          2. contraindication to treatment with heparins&#xD;
&#xD;
          3. uncontrolled hemorrhage&#xD;
&#xD;
          4. Any comorbidity involving a therapeutic limitation and / or a life expectancy &lt;6&#xD;
             months&#xD;
&#xD;
          5. concomitant antiplatelet therapy (aspirin, clopidogrel, ticlopidine, dipyridamole,&#xD;
             sulfinpyrazone, dextran 40, or other anticoagulants&#xD;
&#xD;
          6. and continued concomitant NSAIDs, salicylates, corticosteroids&#xD;
&#xD;
          7. existence of clinically significant esophageal varices / severe gastropathy of portal&#xD;
             hypertension without their having been previously treated with primary / secondary&#xD;
             prophylaxis (endoscopic variceal ligation / non cardioselective beta blockers)&#xD;
&#xD;
          8. Refusal to participate in the study, or to sing informed consent&#xD;
&#xD;
          9. Pregnancy or lactation&#xD;
&#xD;
         10. HIV infection&#xD;
&#xD;
         11. platelet count &lt;20,000 platelets / dl&#xD;
&#xD;
         12. renal clearance below 30ml / min&#xD;
&#xD;
         13. portal vein thrombosis or peripheral thrombosis diagnosed at admission&#xD;
&#xD;
         14. presence of procoagulant factor previously known&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bemiparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

